Novo Nordisk Study Data: Hemophilia Breakthroughs and Pipeline Updates
Will Novo Nordisk’s impressive new hemophilia data be enough to offset Eli Lilly’s aggressive market share gains in the obesity sector? Maik Kemper Editor in Chief How does…
Novo Nordisk ADA +2.3%: CagriSema Data Back in Focus
Can Novo Nordisk ADA data finally give investors a reason to believe the GLP-1 leader can regain momentum? Maik Kemper Editor in Chief The conference highlights the strength…